Uromigos-ESMO

The UromigosThe Uromigos | September 13, 2022
Peter O'Donnell describes the randomized phase 2 study on enfortumab vedotin and pembrolizumab against pembrolizumab alone.
Read More
The UromigosThe Uromigos | September 12, 2022
Nizar Tannir describes this randomized phase 3 study on bempegaldesleukin plus nivolumab as presented at ESMO.
The UromigosThe Uromigos | September 11, 2022
The phase III PRESTO study examined the effects of androgen suppressants on biochemically relapsed prostate cancer. 
The UromigosThe Uromigos | September 11, 2022
Axel Bex summarizes the ipi/nivo, pembro and atezo studies that were presented at ESMO 2022. 
The UromigosThe Uromigos | September 10, 2022
Mohamad Allaf gives a recap of the open-label PROSPER study on neoadjuvant nivolumab in RCC.
The UromigosThe Uromigos | September 2, 2022
Chris Sweeney joins to talk about potential highlights to be presented at ESMO 2022.
The UromigosThe Uromigos | September 19, 2021
Dr. Naveed Vasudev discusses IPI dosing and findings from the PRISM study.
The UromigosThe Uromigos | September 17, 2021
Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.
The UromigosThe Uromigos | September 21, 2020
Dr. Cora Sternber discusses AMG 160 and the future of immunotherapy in CRPC.
The UromigosThe Uromigos | September 20, 2020
Chris Sweeney discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC, a positive R3 trial in the ESMO plenary session.
The UromigosThe Uromigos | September 20, 2020
Dr. Richard Cathomas goes into the detail of chemo immune combinations and what to do next.
The UromigosThe Uromigos | September 19, 2020
Dr. Toni Choueiri and the Uromigos attempt to put the data into context with the other available combinations.
The UromigosThe Uromigos | September 19, 2020
Matt Galsky tries to get to the bottom of whether these data has made any difference in treatment and future plans.
Advertisement
Advertisement